NCT06705686View on ClinicalTrials.gov

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

March 30, 2028

Conditions
Metastatic Castration-resistant Prostate Cancer (CRPC)Metastatic Castration-resistant Prostate Carcinoma
Interventions
DRUG

(R)-9bMS

(R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Washington University School of Medicine

OTHER

collaborator

University of Wisconsin, Madison

OTHER

lead

TechnoGenesys, Inc.

INDUSTRY